Moreover, CX-5461 is currently in clinical trial in BRCA mutant breast cancer (Clinical trial identification: NCT02719977) and so we have considered this using an ovarian cancer model with BRCA2 mutation. The gene discussed is BRCA2; the disease is ovarian cancer.